Bioassociate has today published an article on PharmaPhorum about the fact that bulky in-house R&D is quickly becoming a thing of the past. With better outsourcing capabilities, conglomerates are “hollowing out”, whilst new entrants are beginning to operate on fully-outsourced business models.
There are now many companies operating on a model based on outsourcing of 50%+ of their pipeline.
No comments:
Post a Comment